Art Levin serves on the Board of Directors for Avidity Biosciences, Inc., Stoke Therapeutics, Ascidian Therapeutics, and Comanche Biopharma. Since May 2007, Art has been a Senior Consultant at Levin BioScience. Previously, Art held significant leadership roles including Executive Vice President and Chief Scientific Officer at Avidity Biosciences, Executive Vice President of Research and Development at miRagen Therapeutics, and Chief Development Officer and President of the US Subsidiary at Santaris Pharma a/s. Art's extensive background in oligonucleotide-based therapeutics spans nearly 20 years, with foundational experience at Isis Pharmaceuticals and Hoffmann-La Roche. Art's educational credentials include a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, a postdoctoral degree from CIIT, and a BS in Biology from Muhlenberg College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices